Myriad Genetics Inc

MYGN is in a Stage 2 advancing regime with a clear sequence of higher highs and higher lows supported by rising EMAs and bullish continuation patterns; however, price is extremely overbought and extended above the EMAs near the declining 200-day SMA, so execution is deferred until a pullback into the rising short-term EMAs and consolidation resolution offers a better entry.

• ↑Hereditary cancer test volumes rose 14% YoY in Q1
• ↑AI-enhanced Prolaris prostate test and First Gene assay launch set for 2026
• ↓Prenatal testing revenue fell 15% in Q1 due to operational issues